Nasus Pharma Ltd. NSRX 深 沪
等待开盘 06-30 09:30:00 美东时间
3.45
+0.130
+3.92%
华盛通- 最 高3.55
- 今 开3.35
- 成交量 3.65万股
- 最 低 3.3119
- 昨 收 3.32
- 总市值 4040.23万
- 52周最高 9.9899
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 1.98
- 委 比 0.00%
- 总股本 1171.08万
- 历史最高 9.9899
- 量 比 1.40
- 振 幅 7.17%
- 历史最低 1.98
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
Nasus Pharma Ltd. announced that its management will present at the Zacks Life Sciences Investor Forum on June 24-25, 2026. The virtual event will feature live, interactive sessions where investors can submit questions to management. Nasus Pharma, a clinical-stage company, is developing innovative intranasal powder products for acute medical conditions. Its NS002 product is a needle-free epinephrine option for anaphylaxis patients. The company’s ...
06-22 12:00
Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV
Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results from a
06-09 20:02
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Nasus Pharma announced positive preclinical results for NS003, its intranasal powder formulation of ondansetron, showing comparable pharmacokinetics and safety to IV ondansetron in animal studies. The company plans to initiate a first-in-human PK study in Q3 2026, targeting unmet needs in chemotherapy and post-operative nausea and vomiting.
06-09 12:00
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
Nasus Pharma will host a virtual KOL event on June 10, 2026, featuring Michael S. Blaiss, MD, and Joel Brooks, DO, MPH, to discuss anaphylaxis treatment needs. The event will highlight NS002, the company's epinephrine intranasal powder candidate, which shows faster absorption than EpiPen®. NS002 aims to provide a needle-free alternative for anaphylaxis treatment, addressing challenges faced by pediatric patients. The event includes a Q&A session ...
06-01 12:00
美股夜盘 | 课标科技涨55.26%，Real Messenger Corporation Class A涨25.03%
Replimune涨-62.61%；Nasus Pharma Ltd.涨-15.91%；雷亚电子涨-15.87%
04-13 08:10
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Nasus Pharma Ltd. reports FY results
Nasus Pharma Ltd. press release (NSRX): FY Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, Nasus had cash, cash equivalents and marketable securities of $4.3 million, compar...
03-25 21:17
Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of its annual report on
03-25 21:03
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma reported positive Phase 2 results for NS002, an intranasal epinephrine powder for anaphylaxis, showing faster absorption than EpiPen®. They plan a pivotal study for Q4 2026, with a potential NDA submission. The company is also advancing NS003 (ondansetron for chemotherapy-induced nausea) and NS004 (metabolic disorders) toward first-in-human studies in H2 2026. With strong cash reserves, Nasus is well-funded to support its pipeline ex...
03-25 13:00
美股夜盘 | 正业生物涨35.07%，Blue Gold涨31.43%
正业生物涨35.07%；Blue Gold涨31.43%；QVC Group, Inc. Class A涨23.60%
03-23 15:02
